> **Layer 1** · Medicine & Health Sciences · `H11-ALLERGOLOGIA`

## Purpose
The H11-ALLERGOLOGIA agent provides specialized cognitive processing for allergic diseases, hypersensitivity reactions, and immunological disorders related to allergens. It acts as the core substrate module for analyzing IgE-mediated reactions, anaphylaxis trajectories, and desensitization protocols.

By modeling the complex interactions between environmental triggers, genetic predispositions, and the immune system, this agent allows the H11 substrate to intelligently evaluate patient risk profiles and simulate long-term immunotherapy outcomes.

## Technical Deep-Dive
At its core, H11-ALLERGOLOGIA employs a bipartite graph network to model antigen-antibody interactions and mast cell degranulation pathways. This is coupled with a Bayesian inference engine that updates hypersensitivity probabilities based on patient exposure history and symptomatic manifestations.

The agent uses a compartmental pharmacokinetic-pharmacodynamic (PK/PD) model for predicting the efficacy and safety of subcutaneous (SCIT) and sublingual (SLIT) immunotherapy. It models the shift from Th2 to Th1 immune responses, incorporating differential equations to track specific IgE and IgG4 levels over time.

Additionally, the agent includes an anaphylaxis early-warning module (AEWM) that analyzes continuous vital sign data (if available) alongside real-time exposure variables to calculate a time-to-shock probability, utilizing a temporally-weighted hidden Markov model (HMM).

## Architecture

### Input Contract
| Field | Type | Description |
|-------|------|-------------|
| `patient_atopy_profile` | `AtopyProfile` | Genetic and phenotypic markers of atopy. |
| `exposure_events` | `List[ExposureEvent]` | Chronological record of allergen exposures. |
| `ige_titers` | `Dict[str, float]` | Specific IgE levels for known allergens. |

### Output Contract
| Field | Type | Description |
|-------|------|-------------|
| `reaction_probability` | `float` | Likelihood of severe hypersensitivity reaction. |
| `immunotherapy_plan` | `DesensitizationProtocol` | Recommended protocol for allergen tolerance induction. |
| `trajectory_forecast` | `ImmuneShiftForecast` | Projected Th1/Th2 balance over a specified timeline. |

### State Schema
The agent maintains an `ImmuneStateMatrix` which tracks the half-lives of circulating antibodies, memory B-cell persistence factors, and current therapeutic suppression levels.

## Dependencies
### Upstream (depends on)
- `H11-IMMUNOLOGIA`: Provides baseline immune system parameters.
- `H11-DERMATOLOGIA`: For skin-prick test data and atopic dermatitis markers.

### Downstream (feeds into)
- `H11-PULMONOLOGIA`: For asthma comorbidity risk assessment.
- `H11-PHARMACOLOGIA`: To adjust antihistamine and biological agent dosing.

## Failure Modes
- **Antibody Cross-Reactivity Hallucination**: Incorrectly predicting cross-reactivity between phylogenetically unrelated proteins.
- **Biphasic Reaction Miss**: Failing to predict the secondary phase of anaphylaxis due to incomplete temporal modeling.
- **Desensitization Drift**: Overestimating the durability of induced tolerance post-immunotherapy cessation.

## Performance Characteristics
Latency is typically under 120ms for static profiling. Dynamic AEWM evaluation executes within 15ms per time-step. Memory footprint is dominated by the allergen cross-reactivity matrix (~45MB).

## Research References
1. Akdis, C. A., & Akdis, M. (2015). Advances in allergen immunotherapy. *Gastroenterology & Hepatology*.
2. Jutel, M., et al. (2020). Biomarkers in allergen immunotherapy. *Allergy*.

## Implementation Notes
Implement the cross-reactivity matrix using sparse tensor representations to optimize memory. The PK/PD model should use a stiff ODE solver (e.g., Radau) due to the rapid dynamics of mast cell degranulation.
